Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III study

被引：1
|
作者：
Kuboki, Y. [1 ]
Pietrantonio, F. [2 ]
Salvatore, L. [3 ]
Esaki, T. [4 ]
Modest, D. P. [5 ]
Paez, D. [6 ]
Taieb, J. [7 ]
Ruiz, E. [8 ,9 ]
Kim, T. W. [10 ]
Meriggi, F. A. [11 ]
Cunningham, D. [12 ,13 ]
Yeh, K-H. [14 ]
Chan, E. [15 ]
Chao, J. [16 ]
Strydom, N. [17 ]
Saportas, Y. [18 ]
Tran, Q. [19 ]
Cremolini, C. [20 ]
Fakih, M. [21 ]
机构：
[1] Natl Canc Ctr Hosp East, Expt Therapeut & GI Oncol Dept, Kashiwa, Chiba, Japan
[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy
[3] Fdn Policlin Univ Agostino Gemelli IRCC, Dipartimento Oncol, Rome, Italy
[4] Natl Hosp Org, Med Oncol, Kyushu Canc Ctr, Fukuoka, Japan
[5] Charite Univ Med Berlin, Dept Med Hematol Oncol & Tumorimmunol, Berlin, Germany
[6] Hosp Santa Creu & Sant Pau, Dept Med Oncol, Barcelona, Spain
[7] Hop European George Pompidou, Gastroenterol & Digest Oncol Dept, Paris, France
[8] INCAN Inst Nacl Cancerol, GI Oncol Dept, Ciudad De Mexico, Mexico
[9] INCAN Inst Nacl Cancerol, Translat Med Lab, Ciudad De Mexico, Mexico
[10] Univ Ulsan, Asan Med Ctr, Coll Med, Oncol Dept, Seoul, South Korea
[11] Fdn Poliambulanza Ist Osped, Oncol Dept, Brescia, Italy
[12] Inst Canc Res, Med Dept, Sutton, Surrey, England
[13] Royal Marsden Hosp, Sutton, Surrey, England
[14] NTUH Natl Taiwan Univ Hosp, Dept Oncol, Taipei, Taiwan
[15] Amgen Inc, Global Dev, Thousand Oaks, CA USA
[16] Amgen USA, Oncol Therapeut Area, Seattle, WA USA
[17] Amgen Inc SSF, Clin Pharmacol, San Francisco, CA USA
[18] Amgen Headquarters USA, Global Safety, Thousand Oaks, CA USA
[19] Amgen Headquarters USA, Biostat, Thousand Oaks, CA USA
[20] AOU Pisana Stabilimento Santa Chiara, Polo Oncol, Pisa, Italy
[21] City Hope Comprehens Canc Ctr, Med Oncol Therapeut Res, Duarte, CA USA
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.226
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
91MO
引用
收藏
页码：S1504 / S1505
页数：2
相关论文
共 50 条
  • [41] A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
    Kim, Tae Won
    Elme, Anneli
    Kusic, Zvonko
    Park, Joon Oh
    Udrea, Anghel Adrian
    Kim, Sun Young
    Ahn, Joong Bae
    Villalobos Valencia, Ricardo
    Krishnan, Srinivasan
    Bilic, Ante
    Manojlovic, Nebojsa
    Dong, Jun
    Guan, Xuesong
    Lofton-Day, Catherine
    Jung, A. Scott
    Vrdoljak, Eduard
    BRITISH JOURNAL OF CANCER, 2016, 115 (10) : 1206 - 1214
  • [42] Asian subgroup analysis of the phase III LEAP-017 trial of lenvatinib plus pembrolizumab vs standard-of-care in previously treated metastatic colorectal cancer (mCRC)
    Xu, R-H.
    Chen, Z.
    Teng, H-W.
    Pan, H.
    Zhong, H.
    Takashima, A.
    Yang, T-S.
    Yeh, Y-M.
    Deng, Y.
    Kim, T. W.
    Kim, T-Y.
    Park, J. O.
    Lee, M. A.
    Lee, S.
    Yeh, K-H.
    Yoshino, T.
    Fu, R.
    Jain, R.
    Adelberg, D. E.
    Kawazoe, A.
    ANNALS OF ONCOLOGY, 2023, 34 : S1508 - S1509
  • [43] A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer
    Tae Won Kim
    Anneli Elme
    Zvonko Kusic
    Joon Oh Park
    Anghel Adrian Udrea
    Sun Young Kim
    Joong Bae Ahn
    Ricardo Villalobos Valencia
    Srinivasan Krishnan
    Ante Bilic
    Nebojsa Manojlovic
    Jun Dong
    Xuesong Guan
    Catherine Lofton-Day
    A Scott Jung
    Eduard Vrdoljak
    British Journal of Cancer, 2016, 115 : 1206 - 1214
  • [44] MATCHING-ADJUSTED INDIRECT COMPARISON (MAIC) IN PREVIOUSLY TREATED KRAS G12C-MUTATED ADVANCED/METASTATIC NON-SMALL CELL LUNG CANCER (A/MNSCLC): ADAGRASIB VERSUS SOTORASIB
    Bouwmeester, W.
    Laurie, M.
    Korytowsky, B.
    Grevinga, M.
    Qian, C.
    Berardi, A.
    Gao, S.
    Stenehjem, D.
    VALUE IN HEALTH, 2023, 26 (12) : S31 - S31
  • [45] Final results from a phase III trial evaluating panitumumab (pmab) plus best supportive care (BSC) vs BSC in chemorefractory wild-type (WT) KRAS exon 2 and WT RAS metastatic colorectal cancer (mCRC).
    Kim, Tae Won
    Elme, Anneli
    Kusic, Zvonko
    Park, Joon Oh
    Udrea, Anghel Adrian
    Kim, Sun Young
    Ahn, Joong Bae
    Valencia, Ricardo Villalobos
    Srinivasan, Krishnan
    Bilic, Ante
    Manojlovic, Nebojsa
    Dong, Jun
    Guan, Xuesong
    Lofton-Day, Catherine
    Jung, A. Scott
    Vrdoljak, Eduard
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [46] Lenvatinib plus pembrolizumab versus standard of care for previously treated metastatic colorectal cancer (mCRC): the phase 3 LEAP-017 study
    Kawazoe, A.
    Xu, R.
    Passhak, M.
    Teng, H.
    Shergill, A.
    Gumus, M.
    Qvortrup, C.
    Stintzing, S.
    Towns, K.
    Kim, T.
    Shiu, K.
    Cundom, J.
    Ananda, S.
    Lebedinets, A.
    Fu, R.
    Jain, R.
    Adelberg, D.
    Heinemann, V.
    Yoshino, T.
    Elez, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S179 - S179
  • [47] Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated KRAS G12C-Mutated Non-Small-Cell Lung Cancer: 2-Year Analysis of CodeBreaK 100
    Dy, Grace K. K.
    Govindan, Ramaswamy
    Velcheti, Vamsidhar
    Falchook, Gerald S. S.
    Italiano, Antoine
    Wolf, Jurgen
    Sacher, Adrian G. G.
    Takahashi, Toshiaki
    Ramalingam, Suresh S. S.
    Dooms, Christophe
    Kim, Dong-Wan
    Addeo, Alfredo
    Desai, Jayesh
    Schuler, Martin
    Tomasini, Pascale
    Hong, David S. S.
    Lito, Piro
    Tran, Qui
    Jones, Simon
    Anderson, Abraham
    Hindoyan, Antreas
    Snyder, Wendy
    Skoulidis, Ferdinandos
    Li, Bob T. T.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (18) : 3311 - +
  • [48] Analysis of RAS/BRAF mutations in a randomized phase II WJOG6510G study of panitumumab plus irinotecan versus cetuximab plus irinotecan in chemorefractory metastatic colorectal cancer.
    Nishina, Tomohiro
    Taniguchi, Hiroya
    Sakai, Daisuke
    Kawakami, Hisato
    Sugimoto, Naotoshi
    Hara, Hiroki
    Esaki, Taito
    Denda, Tadamichi
    Makiyama, Akitaka
    Tsuda, Masahiro
    Okuda, Hiroyuki
    Izawa, Naoki
    Hosokawa, Ayumu
    Yamazaki, Kentaro
    Tokunaga, Shinya
    Moriwaki, Toshikazu
    Tsuji, Akihito
    Koh, Yasuhiro
    Kishimoto, Junji
    Muro, Kei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [49] Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC)
    Peeters, Marc
    Oliner, Kelly S.
    Price, Timothy Jay
    Cervantes, Andres
    Sobrero, Alberto F.
    Ducreux, Michel
    Hotko, Yevhen
    Andre, Thierry
    Chan, Emily
    Lordick, Florian
    Punt, Cornelis J. A.
    Strickland, Andrew
    Wilson, Gregory
    Ciuleanu, Tudor-Eliade
    Roman, Laslo
    Van Cutsem, Eric
    Tian, Ying
    Jung, Andre Scott
    Sidhu, Roger
    Patterson, Scott D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [50] CodeBreak 200: A phase III multicenter study of sotorasib (AMG 510), a KRAS(G12C) inhibitor, versus docetaxel in patients with previously treated advanced non-small cell lung cancer (NSCLC) harboring KRAS p.G12C mutation
    Reck, M.
    Spira, A.
    Besse, B.
    Wolf, J.
    Skoulidis, F.
    Borghaei, H.
    Goto, K.
    Park, K.
    Griesinger, F.
    Felip, E.
    Boyer, M.
    Barrios, C. H.
    Goss, G.
    Yang, H.
    Obiozor, C.
    Ramalingam, S. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S894 - S895
12345